Mechanism of action
Metamizole exerts its analgesic and antipyretic effects through multiple pathways, though the exact mechanism remains incompletely understood. The primary mechanisms include:
Cyclooxygenase inhibition: Metamizole and its active metabolites inhibit both COX-1 and COX-2 enzymes, reducing prostaglandin synthesis. This action is predominantly central rather than peripheral, which may explain its lower gastrointestinal toxicity compared to traditional NSAIDs.
Central nervous system effects: The drug may activate descending inhibitory pain pathways. Active metabolites are proposed to interact with the endocannabinoid system and may enhance opioidergic and serotonergic neurotransmission in pain modulation pathways, though these mechanisms are not definitively established.
Antipyretic action: Metamizole reduces fever by inhibiting prostaglandin E2 synthesis in the hypothalamic thermoregulatory center, making it particularly effective for high fever resistant to paracetamol or ibuprofen.
Spasmolytic properties: The drug exhibits direct smooth muscle relaxant effects, contributing to efficacy in biliary and renal colic.
Metamizole is a prodrug rapidly hydrolyzed to 4-methylaminoantipyrine (4-MAA), the primary active metabolite responsible for therapeutic effects.
- Metamizole is banned in the US and UK due to risk of fatal agranulocytosis (idiosyncratic, not dose-dependent).
- Mechanism: non-selective COX inhibition; proposed central cannabinoid CB1 and opioidergic pathway involvement.
- First-line for acute postoperative pain and biliary/renal colic in countries where it is available.
- Agranulocytosis typically occurs within the first week of treatment; requires immediate discontinuation and G-CSF.
- Unlike NSAIDs, metamizole has potent spasmolytic effects on smooth muscle (useful for colic).
- Metabolized to active metabolites (4-methylaminoantipyrine); long duration of action despite short half-life.
- Can cause anaphylactoid reactions (non-IgE-mediated) especially with rapid IV administration.
- Superior analgesic efficacy to paracetamol; comparable to ketorolac for acute pain.
Indications
Metamizole is reserved for specific clinical situations where other analgesics are inadequate or contraindicated:
Acute severe pain:
- Postoperative pain management
- Cancer pain (as part of multimodal analgesia)
- Renal colic and biliary colic
- Acute traumatic pain
High fever: Used when fever is unresponsive to paracetamol or NSAIDs, particularly in hospitalized patients. Often employed in emergency departments for rapid fever reduction.
Regional variations: Metamizole remains first-line in many European, Latin American, and Asian countries for moderate to severe acute pain. In countries where it is available, it is valued for strong analgesic efficacy comparable to NSAIDs with potentially lower gastrointestinal and cardiovascular risks.
Special populations: Sometimes preferred in patients with contraindications to NSAIDs (peptic ulcer disease, cardiovascular disease) or when opioid-sparing analgesia is desired, though agranulocytosis risk must be carefully weighed.
Pharmacokinetics
Absorption: Metamizole is rapidly and completely absorbed after oral administration. The prodrug undergoes immediate non-enzymatic hydrolysis in gastric juice.
Metabolism: Extensive hepatic metabolism produces four main metabolites:
- 4-methylaminoantipyrine (4-MAA): primary active metabolite
- 4-aminoantipyrine (4-AA): active
- 4-formylaminoantipyrine (4-FAA): active
- 4-acetylaminoantipyrine (4-AcAA): less active
Distribution: Metabolites are widely distributed with good tissue penetration. Crosses the placenta and enters breast milk.
Elimination: Primarily renal excretion of metabolites. The half-life of 4-MAA is approximately 2.5-4 hours. Dosing should be adjusted in severe renal impairment.
Bioavailability: Oral bioavailability is approximately 85-90%. Intravenous and intramuscular routes provide rapid onset suitable for acute pain.
Time to peak effect: Analgesic effects begin within 20-30 minutes of oral administration and 10-15 minutes after parenteral dosing.
Adverse effects
Hematologic (most serious):
- Agranulocytosis: Rare (incidence 0.2-2 per million exposures) but potentially fatal. May be immune-mediated or due to direct toxic effects. Risk increases with duration of use beyond one week. Presents with fever, sore throat, oral ulcers, and infections. Requires immediate discontinuation and hematologic evaluation.
- Aplastic anemia (extremely rare)
- Thrombocytopenia
Hypersensitivity reactions:
- Anaphylaxis and anaphylactoid reactions (more common with IV administration)
- Urticaria, angioedema
- Bronchospasm (particularly in patients with analgesic intolerance or asthma)
- Fixed drug eruption
Cardiovascular: Severe hypotension, especially with rapid intravenous injection. Risk factors include volume depletion and preexisting hypotension.
Renal: Acute interstitial nephritis (rare), particularly with prolonged use.
Gastrointestinal: Generally lower incidence than traditional NSAIDs, but nausea, vomiting, and epigastric discomfort may occur.
Hepatic: Transaminase elevations (uncommon).
Other: Red discoloration of urine (harmless metabolite; reassure patients).
The risk-benefit profile limits metamizole to short-term use in most countries where it remains available.
Contraindications and warnings
Absolute contraindications:
- Known hypersensitivity to metamizole or other pyrazolones
- History of agranulocytosis or bone marrow disorders
- Acute intermittent porphyria (may precipitate attacks)
- Glucose-6-phosphate dehydrogenase deficiency (hemolysis risk)
- Third trimester of pregnancy (risk of premature closure of ductus arteriosus)
Relative contraindications and warnings:
- Asthma or chronic urticaria (increased risk of bronchospasm)
- Severe hepatic or renal impairment
- Systolic blood pressure below 100 mmHg (hypotension risk)
- First and second trimester pregnancy (use only if clearly needed)
- Lactation (discontinue breastfeeding or avoid drug)
Regulatory status: Metamizole is banned or not approved in the United States, United Kingdom, Sweden, and several other countries due to agranulocytosis concerns. It remains widely available in Germany, Spain, Latin America, and many other regions with varying restrictions.
Monitoring: For use exceeding a few days, consider baseline complete blood count and periodic monitoring, though routine monitoring does not prevent idiosyncratic reactions.
Patient education: Counsel patients to immediately report fever, sore throat, mouth ulcers, or signs of infection and discontinue the drug.
Drug interactions
Anticoagulants: Metamizole may displace warfarin from protein binding sites and enhance anticoagulant effect. Monitor INR if coadministered. Similar caution with direct oral anticoagulants.
Cyclosporine: Metamizole reduces cyclosporine plasma levels through induction of hepatic metabolism. Measure cyclosporine levels and adjust dosing as needed.
Methotrexate: Potential for increased methotrexate toxicity through reduced renal clearance, similar to NSAID interactions.
Chlorpromazine: Concurrent use may lead to severe hypothermia. Avoid combination or monitor temperature closely.
Alcohol: May enhance sedative effects and increase risk of hypotension.
Antihypertensives: Potential for additive hypotensive effects, particularly with intravenous metamizole administration.
Other analgesics: Avoid concurrent use of multiple NSAIDs or pyrazolones due to increased adverse effect risk without added benefit.
Cytochrome P450: Metamizole metabolites may have minor effects on hepatic enzyme activity, though clinically significant interactions are uncommon.
The relatively short duration of metamizole use in clinical practice limits the significance of many potential interactions.
Clinical pearls
Regulatory geography: Know that metamizole is a high-yield topic because availability varies dramatically by country—banned in the US and UK but widely used elsewhere. Exam questions often test awareness of agranulocytosis as the reason for these restrictions.
Agranulocytosis presentation: Classic presentation includes fever, severe sore throat, oral ulcers, and profound neutropenia developing within the first week of treatment. Immediate discontinuation and hospitalization with broad-spectrum antibiotics are essential. Granulocyte colony-stimulating factor is part of standard management.
Fever reduction: Metamizole is particularly effective for rapid antipyresis in hospitalized patients with high fever unresponsive to first-line agents. This remains a common indication in countries where it is available.
Injection technique: Intravenous metamizole must be given slowly (over at least 5-10 minutes) to minimize hypotension and anaphylactoid reaction risk. Never give rapid IV bolus.
Alternative when NSAIDs contraindicated: In regions where available, metamizole offers opioid-sparing analgesia for patients with peptic ulcer disease or cardiovascular contraindications to traditional NSAIDs.
Urine discoloration: Red-colored urine is a harmless effect of metamizole metabolites. Differentiate from hematuria by dipstick testing.
Duration limits: Best practice restricts metamizole to short-term use (generally less than one week) to minimize agranulocytosis risk, though the reaction is idiosyncratic rather than dose-dependent.
Exam strategy: In clinical vignettes mentioning metamizole use followed by fever and pharyngitis, think agranulocytosis. If a question describes a country where metamizole is used, consider it as a potential cause of unexplained fever or hypersensitivity reactions.
Spasmolytic advantage: The direct smooth muscle relaxant effect makes metamizole particularly effective for visceral pain (biliary and renal colic), distinguishing it from standard NSAIDs.
METAMIZOLE AGRANULOCYTOSIS: ME-ta-MI-zo-le = ME-dullary Myeloid Inhibition (bone marrow suppression causing agranulocytosis)
Practice questions
1. A 45-year-old man in Spain presents to the emergency department with sudden onset severe right flank pain radiating to the groin. He is diagnosed with renal colic from a ureteral stone. The physician administers an analgesic that provides excellent pain relief. Two days later, the patient develops fever, sore throat, and oral ulcers. Laboratory studies show WBC 1,200/μL with absolute neutrophil count of 300/μL. Which medication was most likely administered?
2. A 32-year-old woman in Germany with fever to 39.5°C, severe pharyngitis, and oral ulcers presents after 10 days of metamizole therapy. Labs show WBC 1,100/mm³, absolute neutrophil count 100/mm³. She appears septic with BP 95/60 mmHg. What is the most appropriate immediate management?
3. A 28-year-old woman in Germany with acute intermittent porphyria presents with severe migraine. Her neurologist considers various analgesic options. Past treatments included paracetamol with limited effect. Physical examination shows no focal neurological deficits. Which of the following medications is absolutely contraindicated in this patient?
Frequently asked questions
Why is metamizole banned in the United States?
Metamizole is banned in the US due to the risk of agranulocytosis, a rare but potentially fatal blood disorder. The FDA withdrew approval in 1977 after reports of fatal cases, though the absolute risk is estimated at 0.2-2 cases per million users per year. Despite being widely used in Europe, Latin America, and other regions, the US maintains the ban based on the severity of the adverse effect.
What are the main side effects of metamizole?
The most serious side effect is agranulocytosis (severe reduction in white blood cells), which is idiosyncratic and can be fatal. Other adverse effects include anaphylactoid reactions (especially with IV use), hypotension, skin rashes, and gastrointestinal upset. Unlike traditional NSAIDs, metamizole causes minimal gastrointestinal ulceration and has less impact on renal function and platelet aggregation.
How does metamizole work as a painkiller?
Metamizole works through multiple mechanisms. It non-selectively inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis predominantly in the central nervous system. Evidence suggests its active metabolites may activate cannabinoid CB1 receptors and modulate opioidergic pathways centrally, providing additional analgesia. It also has direct spasmolytic effects on smooth muscle, making it particularly effective for visceral pain like biliary or renal colic.
Is metamizole stronger than ibuprofen?
Metamizole generally provides superior analgesia compared to ibuprofen for acute moderate to severe pain. Clinical trials show it is comparable to ketorolac and more effective than paracetamol or standard-dose NSAIDs. It is particularly effective for postoperative pain, colic, and cancer pain. However, its use is restricted in many countries due to the agranulocytosis risk, while ibuprofen has a well-established safety profile.
What is the difference between metamizole and paracetamol?
Metamizole and paracetamol are both non-opioid analgesics and antipyretics, but differ significantly. Metamizole has stronger analgesic and spasmolytic properties and works through COX inhibition plus proposed cannabinoid pathway modulation. Paracetamol primarily works centrally with weak COX inhibition. The critical difference is safety: metamizole carries a risk of agranulocytosis and is banned in several countries, while paracetamol's main risk is hepatotoxicity in overdose. Metamizole is more effective for acute severe pain.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N02BB02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.